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ABSTRACT
Anaemia and RBC (red blood cell) transfusion may be associated with worse clinical outcomes,
especially with longer blood storage duration prior to transfusion. The mechanisms underlying
these harmful effects are unknown. RBCs have been proposed to buffer plasma S1P (sphingosine 1-
phosphate),a lysophospholipid essential for the maintenanceof endothelial integrity and important
in the regulation of haematopoietic cell trafﬁcking. The present study examined the effect of
anaemia, RBC transfusion and RBC storage duration on plasma S1P levels. Plasma S1P from 30
individuals demonstrated a linear correlation with Hct (haematocrit; R2 =0.51, P<0.001) with no
evidence for a plateau at Hct values as low as 19%. RBC transfusion in 23 anaemic patients with
baseline mean Hct of 22.2+ −0.34% (value is the mean+ −S.D.) increased Hct to 28.3+ −0.6% at 72 h.
DespiteanHctincrease,RBCtransfusionfailedtoelevateplasmaS1Pconsistently.Atrendtowards
an inverse correlation was observed between RBC storage duration and the post-transfusion
increase in plasma S1P. After 30 days of storage, RBC S1P decreased to 19% of that observed in
fresh (3–7-day-old) RBC segments. RBC membranes contain low levels of both S1P phosphatase
and S1P lyase activities that may account for the decline in S1P levels with storage. Our results
support a role for RBCs in buffering plasma S1P and identify a disturbance in the capacity after
transfusion. Changes in S1P content may contribute to an RBC storage lesion. Further studies
should investigate the clinical signiﬁcance of alterations in circulating S1P levels and the potential
value of enriching stored RBCs with S1P.
INTRODUCTION
Anaemia is associated with increased morbidity and
mortality in a variety of clinical settings, including
critically ill patients [1], those with acute coronary
syndromes and surgical patients [2]. Traditionally, RBC
(red blood cell) transfusions have been used to treat
anaemia. Approx. 13.9 million transfusions are given
to 4.8 million patients annually. However, growing
evidence suggests that some of the risks associated
with anaemia may actually arise from RBC transfusion.
Studies have suggested that RBC transfusion may be
associated with heightened systemic inﬂammation [3]
and worse outcomes in certain settings [4–6]. For
example, RBC transfusion correlates with an increased
risk of adverse clinical outcomes in patients with
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myocardial ischaemia, who traditionally were viewed as
a group that would beneﬁt from restoration of RBC
mass to improve oxygenation. In the CRUSADE (Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes with Early Implementation
of the ACC/AHA Guidelines) registry, the ∼10%
of patients who received RBC transfusion were more
likely to die (11.5% compared with 3.8% in-hospital
mortality), suffer myocardial infarction or death (13.4%
compared with 5.8%) and had longer lengths of hospital
stay compared with their non-transfused counterparts
[7]. This increased risk persisted after adjustment for
potentially confounding clinical variables (estimated
adjusted hazard ratio, 3.94) [7]. Likewise, an analysis of
three randomized trials of patients with acute coronary
syndromes revealed a higher 30 day mortality among
those receiving transfusion [8]. The increased risk was
especially evident among transfused patients with Hct
(haematocrit) > 25%.
Long duration of storage (age) of RBCs has also
been associated with worse outcomes after transfusion
[9,10]. For example, the transfusion of RBCs stored for
more than 2 weeks has been associated with an increase
in complications in patients undergoing cardiac surgery
[10]. Those given older blood had higher in-hospital
mortality, a need for intubation beyond 72 h, sepsis and
worse 1 year outcomes as compared with patients who
received newer blood. These and other observations have
spawned the ‘RBC storage lesion’ hypothesis, which
proposes that unfavourable cellular changes occur during
the storage of RBCs [11]. However, the molecular
alterations that might account for dysfunction associated
with RBC storage are not known. Depletion of nitric
oxide and biochemical changes in lipid content may
occur in stored RBCs, with potential prothrombotic or
immunomodulatory effects [12].
Modiﬁcation of RBC phospholipid composition
has been observed during storage. LPCs (lysophos-
phatidylcholines) accumulate in aged RBCs and have
been proposed as a possible mediator of lung injury
after transfusion [13]. RBCs also accumulate, store
and release another lysophospholipid, S1P (sphingosine
1-phosphate) [14], which has been implicated as a
critical regulator of endothelial barrier function [15] and
lymphocyte egress from lymph tissue. The buffering
capacity of RBCs for S1P may be a key determinant
of plasma levels of this important bioactive mediator.
Indeed, anaemia has been associated with lower levels
of plasma S1P in humans [16]. Anaemia and blood
transfusionmaythereforealterplasmaS1Phomoeostasis,
which in turn could affect vascular permeability and
lymphocyte trafﬁcking.
In the present study, we have examined the effect of
anaemia, blood transfusion and RBC storage duration on
S1P levels. Our purpose was to evaluate the role of RBCs
inmaintainingS1Phomoeostasis,todeterminehowRBC
Table 1 Demographic and clinical characteristics of
anaemic patients
Values are means+ −S.D. or percentages.
Characteristic Value
Age (years) 62+ −16




Body mass index (kg/m2) 27.1+ −8.5
transfusionaffectsS1Plevelsandtoascertainwhetherthe
relationship between RBC transfusion and S1P levels is
itself inﬂuenced by RBC storage duration.
MATERIALS AND METHODS
Subjects
Normal donors and patients provided written consent,
and blood was collected according to protocols approved
by the Institutional Review Boards at the University
of Kentucky. Normal donors were recruited from
University staff and laboratory personnel. A total of
36 anaemic patients who had not received a blood
transfusion in the last 30 days were recruited from
the Chandler Medical Center; of these patients, 13
did not receive transfusions and 23 were scheduled
to be transfused as deemed necessary by their
treating physicians. Exclusion criteria included recent
trauma, scheduled surgery, haemodynamic instability
or pregnancy. Demographic characteristics, pertinent
medical history and laboratory values (metabolic panel,
lipid proﬁle, and baseline and post-transfusionHct) were
abstracted from the medical record and are presented
in Table 1. The number of blood units transfused and
the duration of storage of each unit were recorded.
For measurement of plasma levels of S1P, blood was
collected into tubes containing sodium citrate (0.32%
ﬁnal concentration) before transfusion and at times up
to 72 h post-transfusion. Plasma was rapidly separated
by centrifugation, snap-frozen and stored at −80◦Cf o r
further analysis.
Quantiﬁcation of S1P, LPC, sphingosine
and hexadecenal by HPLC–ESI
(electrospray ionization)–MS/MS (tandem
MS)
Lipids were extracted from plasma, RBCs and in
vitro enzyme assays using acidiﬁed organic solvents,
as we have described previously [17]. Analysis of
S1P, sphingosine and hexadecenal (as its semicarbazone
derivative) were accomplished using a Shimadzu UFLC
(ultra-fast liquid chromatography) coupled with an
C   The Authors Journal compilation C   2011 Biochemical Society
© 2011 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Plasma S1P and blood transfusion 567
ABI 4000-Qtrap hybrid linear ion trap triple quad-
rupole mass spectrometer in MRM (multiple reaction
monitoring) mode using C17-S1P, C17-sphingosine
and d5-hexadecenal semicarbazone used as internal
standards. S1P, DH-S1P (dihydro-S1P) and C17-S1P
were separated using an Agilent Zorbax Eclipse XDB
C8 column, 5 μm, 4.6×150 mm2. The mobile phase
consisted of 3:1 methanol/water with formic acid (0.5%)
and 5 mM ammonium formate (0.1%) as solvent A and
99:1 methanol/water with formic acid (0.5%) and 5 mM
ammonium formate (0.1%) as solvent B. For the analysis
of S1P and DH-S1P, separation was achieved using a
gradient of 0% B for 1 min, 0–100% B in the next
1 min, maintained at 100% B for the next 10 min
and equilibrated to the initial conditions in 3 min. The
ﬂow rate was 0.5 ml/min with a column temperature
of 30◦C. The sample injection volume was 10 μl. The
mass spectrometer was operated in the positive ESI
mode with optimal ion source settings determined using
synthetic standards of S1P, DH-S1P and C17-S1P with a
declustering potential of 61 V, entrance potential of 10 V,
collision energy of 23 V, collision cell exit potential of
16 V, curtain gas of 20 lbf/in2 (1 lbf/in2 =6.9 kPa), ion
sprayvoltageof5500 V,ionsourcegas1/gas2of40lbf/in2
and temperature of 550◦C. MRM transitions monitored
were: 366.141/250 for C17-S1P, 382.133/284.2 for DH-
S1P and 380.124/264.1 for S1P.
Sphingosine was analysed using a Waters XTerra
C8, 3.5 μm, 3.0×100 mm2 column. The mobile
phase consisted of 61:39:0.5 methanol/5 mM ammonium
formate/formic acid as solvent A and 90:10:0.5:0.5 acet-
onitrile/chloroform/5 mM ammonium formate/formic
acid as solvent B. Analysis of sphingosine was conducted
by maintaining 0% B for the ﬁrst 3 min, gradually
increasing it from 0% B to 100% B in the next
5 min and maintaining it at 100% B for the last
2 min. Column equilibration time was 3 min. The ﬂow
rate was 0.5 ml/min with a column temperature of
30◦C. The sample injection volume was 10 μl. The
mass spectrometer was operated in the positive ESI
mode with optimal ion source settings determined by a
C17-sphingosine synthetic standard with a declustering
potential of 76 V, entrance potential of 10 V, collision
energy of 29 V, collision cell exit potential of 16 V, curtain
gas of 30 lbf/in2, ion spray voltage of 5500 V, ion source
gas1/gas2 of 40 lbf/in2 and temperature of 550◦C.
Hexadecenal semicarbazone was analysed using a
nucleodur C18 gravity, 5 μM, 125/2 column. The mobile
phaseconsistedof75:25methanol/waterwithformicacid
(0.5%) and 5 mM ammonium formate (0.1%) as solvent
A and 80% [99:1 of methanol/water with formic acid
(0.5%) and 5 mM ammonium formate (0.1%)]+20%
chloroform as solvent B. Analysis of hexadecenal
semicarbazone was conducted by maintaining 0% B
for 1 min and gradually increasing it from 0% B to
100% B over the next 7 min and maintaining it at 100%
B for the last 2 min. Column equilibration time was
3 min. The ﬂow rate was 0.5 ml/min with a column
temperature of 30◦C. The sample injection volume was
10 μl.Themassspectrometerwasoperatedinthepositive
ESI mode with optimal ion source settings determined
by derivatizing synthetic standard of hexadecenal with
semicarbazidehydrochloride,withthefollowingsettings:
declusteringpotentialof101 V,entrancepotentialof10 V,
collision energy of 21 V, collision cell exit potential of
14 V, curtain gas of 20 lbf/in2, ion spray voltage of
5500 V,ionsourcegas1/gas2of40lbf/in2 andtemperature
of 550◦C. The MRM transitions monitored were as
follows: 296.3/279.2, 296.3/253.2 and 296.3/97.3 for
hexadecenalsemicarbazone;and301.3/258.2,301.3/284.3
and 301.3/97 for d5-hexadecenal semicarbazone.
LPCs were quantiﬁed using methods that have been
described previously [18].
Size-exclusion fractionation of plasma
Plasma was subjected to size-exclusion chromatography
usingaSuperdex75HR10/30(1×30cm2)column(Phar-
macia). In brief, 100 μl of plasma was chromatographed
ataﬂowrateof0.5 ml/minusingPBSasthemobilephase.
Atotalof20fractionswerecollected,andtheS1Pcontent
in each fraction was measured by HPLC–ESI–MS/MS as
described above. Lipoprotein-containing fractions were
identiﬁed by immunoblot analysis.
Measurement of S1P in stored blood
Storage segments containing samples of the RBC unit in
integral tubing ﬁlled at the time the unit was prepared
were obtained from 35 different 3–7-day-old RBC units
from the Kentucky Blood Center on two separate
occasions. Lipids were extracted from 50 μlo fR B C s
obtained from these segments. The segments were then
stored at 4◦C under blood bank conditions for an
additional 35 days to produce samples that have ages of
38–43 days, at which time another sample was obtained
for lipid extraction and analysed as described above.
Determination of S1P phosphatase and
lyase activities
RBC membranes were prepared by hypo-osmotic lysis
and repeated washing of freshly isolated RBCs. S1P
lyase and phosphatase activities were determined using
Triton X-100-solubilized substrates and assay conditions
determined previously to be optimal for these enzymes
[19]. S1P phosphatase activity was determined by
monitoring the production of sphingosine using HPLC–
ESI–MS/MS as described above with C17-sphingosine
added as an internal standard to monitor recovery, and
quantiﬁcation of sphingosine was accomplished with
reference to a calibration curve generated using an
authentic standard. S1P lyase activity was determined by
measuring the formation of hexadecenal detected as its
semicarbazone derivative as described previously [20].
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Figure 1 Effect of anaemia on plasma S1P levels and distribution
(A) Total plasma S1P, measured as described in the Materials and methods section, from anaemic patients (n=23) and healthy volunteers (n=4) plotted against
Hct. R2 =0.51 (P <0.001) by linear regression analysis. (B) Representative S1P distribution in fractions of plasma separated by size-exclusion chromatography from
normal and anaemic subjects. The peak of S1P correlated with the elution of HDL, as detected by immunoblotting the fractions for ApoA1. (C) Lack of correlation
between plasma S1P and HDL in subjects (n=10) with anaemia (range, 21–36%). R2 =0.00027 (P =0.97) by linear regression analysis.
Statistical analysis
Results are expressed as means+ −S.D. Means were
compared using paired Student’s t tests (pre- compared
with post-) or unpaired Student’s t tests (one group
compared with another). Associations between two
quantitative variables were assessed by linear regression.
To examine the relationship between duration of RBC
storage and changes in S1P levels post-transfusion, data
wereanalysedbyweightedleast-squareslinearregression
analysis with the weights inversely proportional to
estimates of error variance. When ﬁtting a regression
modelwithS1Pchangeasthedependentvariableanddays
storage as the independent variable, one value appeared
as a potential ‘outlier’ (change in S1P concentration
∼−400 at ∼2 days), with an externally studentized
residual of −3.24, and was the only observation whose
externally studentized residual exceeded 2.50 in absolute
value. Therefore Spearman correlation was determined
with the observation included and excluded. Statistical
signiﬁcance was determined by a P value less than 0.05
using SigmaSTAT version 3.5 (Systat Software).
RESULTS
Anaemia is associated with selective
depletion of HDL (high-density
lipoprotein)-associated S1P
Previous studies have established that RBCs store and
transport S1P and may be important in maintaining
circulating S1P levels [14,21]. In keeping with these
observations, plasma S1P is reportedly to be lower in
anaemic individuals [22]. Our measurements of plasma
S1P in 23 anaemic patients and four healthy donors
conﬁrm and extend this recent report [22]. Plasma S1P
had a strong linear association with Hct (R2 =0.51,
P<0.001),withnosuggestionofaplateaunearthelowest
Hct value of 19% (Figure 1A). S1P in plasma associates
predominately with lipoprotein particles, particularly
HDLs, and also with plasma proteins, most prominently
albumin [21]. To determine whether anaemia alters
the distribution of S1P between these pools, plasma
from normal donors (n=3) and anaemic individuals
(n=3) with HDL levels 40–50 mg/dl was fractionated
by size-exclusion chromatography. Figure 1(B) displays
the representative distribution using the values from
one individual. In normal individuals, 77.4+ −0.6% of
total plasma S1P was found in the HDL-rich fractions,
identiﬁed by their Apo (apolipoprotein) A1 content. In
plasma from anaemic patients, only 41.6+ −9% of total
S1P was found in the HDL-rich fractions (P=0.002),
suggesting that anaemia selectively depletes the HDL-
bound pool of S1P. In keeping with these observations,
S1P levels did not correlate with HDL levels in anaemic
individuals with Hct <36% (Figure 1C; R2 =0.00027,
P=0.97). In this patient population, no signiﬁcant
correlation existed between Hct and HDL.
Transfusion of RBCs variably restores S1P
in anaemic patients
In mice engineered to lack S1P by conditional genetic
inactivation of the two sphingosine kinase enzymes
responsible for S1P production (‘S1P-less’ mice), RBC
transfusionreplenishescirculatingS1P[23].Thereforewe
sought to determine whether RBC transfusions given to
improve Hct in humans increased circulating S1P levels
in23patientswithanaverageHctof22.2+ −1.1%priorto
transfusion. On average, 1.8 units of leucoreduced RBCs
were transfused per patient. At 1 h after transfusion, the
average Hct increased by ∼30% to 28.5+ −2.4% and
remained stable up to 72 h, at which time the average
Hct was 28.3+ −2.9%. Despite the elevation in average
Hct, average plasma S1P increased by <5% at 1h
post-transfusion (Figure 2A). Unlike in pre-transfusion
samples, plasma S1P at 12–24 h after transfusion did
not correlate with Hct (Figure 2B), indicating that
replacement of RBC alone may not restore plasma
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Figure 2 Effect of blood transfusion on plasma S1P levels and distribution
(A) Plasma S1P levels in individuals pre- and 1 h post-transfusion. The mean levels (458+ −161 nM and 465+ −180 nM; P =0.80, as determined using a paired
Student’s t test) are indicated by horizontal bars. (B) Plasma S1P as a function of Hct at 12–24 h after transfusion. Data were analysed by linear regression. (C) S1P
distribution in fractions of plasma separated by size-exclusion chromatography pre- and post-transfusion from an anaemic patient who displayed an increase in total
plasma S1P after transfusion.
Figure 3 Effect of RBC storage duration on post-transfusion
plasma S1P levels
Change in S1P levels from baseline to 12–24 h post-transfusion compared with
the age of the RBC unit transfused. For patients receiving >1 unit, the average
storage duration of transfused units was plotted. R2 =0.085 (P =0.06) by
linear regression analysis with weighted least squares.
S1P levels in anaemic individuals. Indeed, there was
substantial interindividual variability in the response to
transfusion. At 12–24 h after transfusion, plasma S1P
declined in four patients, despite increases in Hct. In
13 individuals, plasma S1P post-transfusion changed
less than 200 nM from pre-transfusion; however, S1P
increased by more than 200 nM in six patients. Plasma
from individuals whose S1P concentrations increased
after transfusion was fractionated by size exclusion. The
increase in plasma S1P paralleled a restoration in HDL-
associated S1P (Figure 2C).
RBC S1P declines with storage
TounderstandwhyRBCtransfusiondidnotconsistently
restore plasma S1P, we examined the relationship
between the age of the RBC unit transfused and the
post-transfusion change in plasma S1P in 22 patients
(Figure 3). When analysed by weighted least-squares
linear regression analysis, there was a negative, but not
statistically signiﬁcant, correlation (P=0.058) between
the age of the RBC unit and the post-transfusion change
in plasma S1P. However, one observation appeared as
a potential ‘outlier’. The Spearman correlation between
S1P change and days storage was −0.547 (P=0.01) with
the observation excluded and −0.354 (P=0.1) with the
observation included. To explore further the relationship
between RBC age and S1P delivery, we measured the
S1P content in RBC storage segments from 3–7-day-
old RBC transfusion units (Figure 4A). In 35 segments,
there was considerable variability between S1P across
different segments from these ‘young’ RBC units, with
up to a 3-fold difference in S1P levels. After storage
of the 35 segments for an additional 35 days, the S1P
content consistently and markedly declined by 81+ −9%.
We next sought to determine the fate of S1P during
storage. S1P can be degraded by lyase and phosphatase
activities. Dephosphorylation of S1P by lipid phosphate
phosphatases yields sphingosine, which accumulates in
RBC segments with storage (Figure 4B). S1P lyase
cleaves S1P at the C2–C3 bond to generate ethano-
lamine phosphate and hexadecenal. With storage, RBC
segments also accumulate hexadecenal (Figure 4C). In
the same samples, aged-associated increases occurred
in LPC, speciﬁcally those of chain lengths 16:0, 18:0, 18:1
and 20:4 (Figure 4D), as reported previously by other
investigators [13].
Degradation of S1P by RBC membrane-
associated lyase and phosphatase
activities
The results obtained with RBC segments suggest the
presence of S1P lyase and phosphatase activities in
stored RBC. However, RBC S1P-degrading activities
have been reported to be undetectable in intact RBCs
or membrane preparations based on measurements made
using radiochemical- or ﬂuorescence-based assays [24].
We used more sensitive MS-based assays to monitor
metabolismofexogenouslyprovidedS1PbyRBCs.RBC
S1P lyase activity was evident when the formation of
hexadecenal,detectedasitssemicarbazonederivative,was
measured under assay conditions established previously
to be optimal for the enzyme (Figure 5A). Likewise, the
presence of S1P phosphatase activity was detected by the
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Figure 4 Effect of RBC storage duration on levels of S1P, its
degradation products and LPC
(A) Effect of RBC storage duration on S1P levels in 50 μl obtained from 10
RBC unit ‘segments’ (numbered 1–10) stored for the indicated times. Results
are given as means+ −S.D. P <0.001, as determined using a paired Student’s
t test. Results are representative of results obtained in different experiments
from 35 segments. (B) Accumulation of sphingosine (Sph) in RBC unit ‘segments’
(numbered 1–10). Results are given as means+ −S.D. (n=10). P =0.005, as
determined using a Student’s t test. (C) Accumulation of hexadecenal in RBC
unit ‘segments’ stored for the indicated times. Results are given as means+ −S.D.
(n=10). P =0.001, as determined using a paired Student’s t test. S1P, Sph
and hexadecenal levels are reported as the amount measured in 50 μl. (D) LPC
content as means+ −S.D. (n=23) in pmol/nmol of lipid phosphate for individual
LPC species denoted by chain length.
appearance of C17-sphingosine after incubation of RBC
membranes with C17-S1P (Figure 5A). S1P lyase and
phosphatase activities in RBC membranes were much
lower than reported in other mammalian tissues and
cell lines, and were only 0.4 and 3% respectively of
those in a mouse liver homogenate assayed in parallel
as a positive control (Figure 5B). Such low levels may
explain previous reports that S1P lyase and phosphatase
Figure 5 Determination of S1P phosphatase and lyase
activity in liver homogenates and RBC membranes
Membrane fractions were prepared from washed RBCs (A) or liver tissue (B). S1P
phosphatase (P’tase) and S1P lyase activities were quantiﬁed by measuring the
rates of formation of sphingosine and hexadecenal (detected as its semicarbazone)
as described in the Materials and methods section.
activities were not detectable in RBCs when less sensitive
assays were employed [24]. The low levels of activity
may be sufﬁcient to degrade RBC S1P during prolonged
storage and account for elevations in both sphingosine
and hexadecenal. RBC release S1P [22], and it is possible
that released S1P is degraded by RBC-surface-associated
lipid phosphate phosphatases.
DISCUSSION
In the vasculature, S1P plays an essential role in
maintaining endothelial barrier function and regulating
immune cell function [15,21,23]. HDL is a major carrier
of plasma S1P, and evidence suggests that some of the
pleotropicbeneﬁcialeffectsofHDLinthecardiovascular
system may involve HDL-mediated delivery of S1P
to vascular cells. Thus the biological activity of S1P
may be regulated by both its total circulating level
and its distribution between RBCs and plasma protein
compartments. Understanding the mechanism(s) that
regulate plasma S1P levels and distribution of plasma
S1P between protein-bound pools may therefore be
important for evaluating the functional consequences
of alterations in circulating S1P levels. RBCs buffer
plasma S1P by sequestering and releasing this bioactive
lipid. Previous work indicates that anaemia in humans is
associated with a reduction in plasma S1P levels without
a change in RBC-associated S1P, suggesting that total
RBC S1P ‘capacity’ inﬂuences plasma S1P levels in
humans, although the same may not be true in mice
[14,22,25]. Both HDL and albumin elicit the release
of S1P from RBCs [22]. These observations, coupled
with the fact that isolated RBCs can take up S1P from
media, have led to a proposed model of circulating
S1P homoeostasis, in which RBCs buffer this lipid and
the binding capacity of plasma components, such as
HDL and albumin, regulate the release of the lipid
from RBCs. The present study identiﬁes an effect of
anaemia on S1P distribution between plasma protein
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pools and extends these observations by describing the
effects of RBC transfusion on S1P homoeostasis. The
ﬁndings may have broad implications for understanding
the mechanisms responsible for the deleterious effects
of RBC transfusions in anaemic patients. Our results
suggest that one potential source for disruption of S1P
homoeostasis in transfusion recipients could be the use
of RBC units with altered S1P content, particularly aged
RBCs in which S1P levels have become depleted.
Our ﬁndings conﬁrm a correlation between RBC
indices and plasma S1P concentration and indicate that
the relationship remains linear at the lowest tested
Hct (19%). Anaemia also predicts a change in plasma
distribution of S1P, with less of the total pool of
S1P associating with HDL in plasma from anaemic
individuals. A recent study establishes that ApoM
content of HDL correlates with human HDL-S1P
levels [26]. Mice with absent or heightened ApoM
expression have corresponding decreases and increases in
plasma S1P respectively. Importantly, genetic deﬁciency
of ApoM in mice, which reduces plasma S1P levels
by approx. 50%, disrupts endothelial barrier function
and promotes permeability [26]. Thus apoM appears
essential for the S1P-protective effects of HDL. The
IC50 for ApoM binding to S1P is approx. 0.9 μM [26],
which is close to the plasma concentration of S1P. Our
results suggest equilibrium between ApoM and RBC-
pools of S1P that may reﬂect the afﬁnity of ApoM
for S1P. Loss of ApoM-associated S1P could diminish
endothelial-protective effects exerted by HDL and
could contribute to a systemic inﬂammatory response
and endothelial dysfunction described in anaemia [12],
whichhasbeencitedasacauseofincreasedmorbidityand
mortality that cannot solely be explained by a decrease in
circulating RBC mass.
Despite lower S1P levels in plasma from anaemic
individuals, RBC transfusion did not consistently
increase plasma S1P, despite consistent improvements
in Hct. One possible explanation for the lack of
an increase in S1P post-transfusion is a decline in
RBC S1P content during storage due to S1P-degrading
activities in RBCs. In support of this possibility, a
trend towards an inverse correlation between the age
of the transfused unit and a change in plasma S1P
was observed. Unfortunately, in the present study, we
did not measure S1P content in the transfused RBC
units, an important value necessary to correlate post-
transfusion changes in plasma S1P with RBC S1P
content.GiventheconsistentandstrikingdeclineinRBC
S1P content during storage, it is reasonable to assume
that the older transfusion units contained less S1P.
However, the RBC S1P content of the younger units (3–
7 days)isvariableandmayalsocontributetoinconsistent
increases in post-transfusion S1P.
In summary, previous studies have identiﬁed a correl-
ation between Hct and circulating S1P levels that is prob-
ably due to the capacity of RBCs to buffer, that is take
up and release S1P. The present work indicates that RBC
transfusion disrupts normal S1P homoeostasis. It may be
possible that a disturbance in S1P levels or distribution
between plasma-protein-associated pools after RBC
transfusionmayalteritsphysiologicaleffects.Twoﬁrmly
established effects of circulating S1P are to maintain
endothelial barrier function and to regulate immune cell
trafﬁcking. ‘S1P-less’ mice develop lung vascular leakage
anddisplayimpairmentoftheS1Pblood–lymphgradient
that mediates egress of lymphocytes from lymphoid
tissue [15,23]. Thus attenuation of S1P signalling may
promote lung permeability and pulmonary oedema,
impair immune cell function and affect infection rates, all
of which are adverse clinical events that occur after trans-
fusion.Indeed,therecognitionoftherisksassociatedwith
transfusion has led to the widespread adoption of strict
indications for transfusion. RBC storage may contribute
to the risk associated with transfusion and therefore un-
derstanding the changes in the properties of stored RBCs
becomes important for modifying practices to improve
the quality of transfused blood and clinical outcomes.
The present work supports the concept that changes
in the lysopholipid content of RBCs during storage
could have biological and clinical ramiﬁcations. One
logical extension of our ﬁndings is to investigate ways of
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